NCT02301962 - Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 28, 2015

Primary Completion Date

June 30, 2021

Study Completion Date

January 31, 2022

Conditions

Cancer

Interventions

DRUG

Panitumumab

Panitumumab is available as a concentrate for solution for infusion (sterile concentrate). It is a colorless solution that may contain, translucent to white, visible amorphous, proteinaceous panitumumab particles. Each milliliter (mL) of concentrate contains 20 mg panitumumab. Each vial contains 100 mg of panitumumab in 5 mL.

Trial Locations (12)

110029

NOT_YET_RECRUITING

DRL Investigational Site, New Delhi

110060

RECRUITING

DRL Investigational Site, New Delhi

141010

RECRUITING

DRL Investigational Site, Ludhiana

400012

NOT_YET_RECRUITING

DRL Investigational Site, Mumbai

422004

RECRUITING

DRL Investigational Site, Nashik

422005

RECRUITING

DRL Investigational Site, Nashik

440026

RECRUITING

DRL Investigational Site, Nagpur

500004

RECRUITING

DRL Investigational Site, Hyderabad

520002

RECRUITING

DRL Investigational Site, Vijayawada

625107

RECRUITING

DRL Investigational Site, Madurai

700156

ACTIVE_NOT_RECRUITING

DRL Investigational Site, Kolkata

302 020

RECRUITING

DRL Investigational Site, Jaipur